Parkman Healthcare Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Parkman Healthcare Partners’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,852	Closed	-$1.06M	–	96
2025 Q4	$1.06M	Sell	22,852 -50,873	-69%	-$2.26M	0.1%	91
2025 Q3	$3.07M	Buy	73,725 +313	+0.4%	+$10K	0.32%	74
2025 Q2	$2.11M	Buy	73,412 +9,472	+15%	+$293K	0.24%	81
2025 Q1	$2.14M	Buy	63,940 +12,807	+25%	+$478K	0.25%	74
2024 Q4	$2.61M	Sell	51,133 -26,490	-34%	-$1.48M	0.35%	64
2024 Q3	$3.97M	Sell	77,623 -63,752	-45%	-$3.29M	0.51%	59
2024 Q2	$6.33M	Buy	141,375 +40,256	+40%	+$1.86M	0.85%	41
2024 Q1	$4.73M	Sell	101,119 -19,533	-16%	-$764K	0.58%	58
2023 Q4	$4.29M	Buy	120,652 +20,652	+21%	+$633K	0.6%	53
2023 Q3	$2.97M	Buy	+100,000	New	+$2.06M	0.54%	54

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Parkman Healthcare Partners's CRNX Position: Q1 2026 in Review

Parkman Healthcare Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 22,852 shares — an estimated $1.06M sold.

Parkman Healthcare Partners first reported a position in CRNX in Q3 2023 and held it in 10 quarters. The position peaked at $6.33M in Q2 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Parkman Healthcare Partners reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Parkman Healthcare Partners sold 22,852 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $1.06M.
Parkman Healthcare Partners first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 10 quarters.
Parkman Healthcare Partners's Crinetics Pharmaceuticals position peaked at $6.33M in Q2 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.